XM does not provide services to residents of the United States of America.
P
P

Pfizer

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Haleon names Dawn Allen as CFO

UPDATE 1-Haleon names Dawn Allen as CFO Adds company context in paragraphs 3, 5 and 6 April 24 (Reuters) - Consumer healthcare firm Haleon HLN.L said on Wednesday that Dawn Allen has been appointed as its new chief financial officer, effective Nov. 1. Allen, 55, currently CFO at British food ingredients maker Tate & Lyle TATE.L , replaces Tobias Hestler.
P
T

Pfizer vs Moderna battle over COVID vaccine patents begins in UK

Pfizer vs Moderna battle over COVID vaccine patents begins in UK By Sam Tobin LONDON, April 23 (Reuters) - Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer PFE.N and its German partner BioNTech 22UAy.DE sued Moderna MRNA.O at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later allegin
P

European Commission Approves Pfizer’s Emblaveo

BRIEF-European Commission Approves Pfizer’s Emblaveo April 22 (Reuters) - Pfizer Inc PFE.N : EUROPEAN COMMISSION APPROVES PFIZER’S EMBLAVEO® FOR PATIENTS WITH MULTIDRUG-RESISTANT INFECTIONS AND LIMITED TREATMENT OPTIONS Source text for Eikon: ID:nBw8nf4H5a Further company coverage: PFE.N
P

Weight-loss drug developer Metsera raises $290 million in funding

Weight-loss drug developer Metsera raises $290 million in funding By Pratik Jain April 18 (Reuters) - Weight-loss drug developer Metsera has raised $290 million in funding, led by biotech investor ARCH Venture Partners as well as participation from firms such as SoftBank and Mubadala Capital, the company said on Thursday. The funding comes at a time when multiple drug companies are competing to grab a slice of the weight-loss drug market, which is estimated by analysts to reach at least $100 bil
N
P

Top US markets regulator probing insider trading guardrails, official says

UPDATE 1-Top US markets regulator probing insider trading guardrails, official says Adds context in paragraphs 2, 6 By Chris Prentice NEW YORK, April 17 (Reuters) - The U.S. Securities and Exchange Commission is scrutinizing whether investment advisers and other firms have strong enough policies to ensure nonpublic information is not misused to gain an illegal edge in trading, a top official told Reuters.
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.